Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Taps Tata Software to Help Enable Tech Development

NEW YORK (GenomeWeb News) — Sequenom today said it has tapped Tata Consultancy Services to develop software products to “empower its customers to discover, analyze, and report genetic information.”
The software will include components that provide access to public and private life sciences databases; integrate bioinformatics and computational biology tools within the framework; and enable the design and execution of workflows.
It will be designed to enable researchers to “create and manage projects for planning user tasks, storing user data, and analyses,” Sequenom said in a statement.
TCS' signal-processing and life sciences group will develop software modules for “improving interfaces to, and signal conditioning of, mass spectrometer data,” Sequenom said.
“The emerging genetics and life sciences sectors present a significant growth opportunity for TCS as it helps us leverage the innovation embedded in this organization,” TCS CEO S. Ramadorai said in the statement.
All development under the agreement will conform to US Food and Drug Administration regulatory standards, Sequenom said.
Financial terms of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.